Does PEMBROLIZUMAB Cause Tumour marker increased? 42 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 42 reports of Tumour marker increased have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.1% of all adverse event reports for PEMBROLIZUMAB.
42
Reports of Tumour marker increased with PEMBROLIZUMAB
0.1%
of all PEMBROLIZUMAB reports
6
Deaths
14
Hospitalizations
How Dangerous Is Tumour marker increased From PEMBROLIZUMAB?
Of the 42 reports, 6 (14.3%) resulted in death, 14 (33.3%) required hospitalization, and 1 (2.4%) were considered life-threatening.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 42 reports have been filed with the FAERS database.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
Which PEMBROLIZUMAB Alternatives Have Lower Tumour marker increased Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G